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A b s t r a c t
Background and aim: High platelet reactivity (HPR) and presence of CYP2C19 loss-of-function alleles are associated with 
higher risk for periprocedural myocardial infarction in clopidogrel-treated patients undergoing percutaneous coronary inter-
vention (PCI). It is unknown whether personalised treatment based on platelet function testing or genotyping can prevent 
such complications.  
Methods: The ONSIDE-TEST is a multicentre, prospective, open-label, randomised controlled clinical trial aiming to assess 
if optimisation of antiplatelet therapy based on either phenotyping or genotyping is superior to conventional care. Patients 
will be randomised into phenotyping, genotyping, or control arms. In the phenotyping group, patients will be tested with the 
VerifyNow P2Y12 assay before PCI, and patients with a platelet reactivity unit greater than 208 will be switched over to prasu-
grel, while others will continue on clopidogrel therapy. In the genotyping group, carriers of the *2 loss-of-function allele will 
receive prasugrel for PCI, while wild-type subjects will be treated with clopidogrel. Patients in the control arm will be treated 
with standard-dose clopidogrel. The primary endpoint of the study is the prevalence of periprocedural myocardial injury within 
24 h after PCI in the controls as compared to the phenotyping and genotyping group. Secondary endpoints include cardiac 
death, myocardial infarction, definite or probable stent thrombosis, or urgent repeat revascularisation within 30 days of PCI. 
Primary safety outcome is Bleeding Academic Research Consortium (BARC) type 3 and 5 bleeding during 30 days of PCI. 
Summary: The ONSIDE TEST trial is expected to verify the clinical utility of an individualised antiplatelet strategy in preventing 
periprocedural myocardial injury by either phenotyping or genotyping. 
Trial registration: ClinicalTrials.gov: NCT01930773.
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INTRODUCTION
Optimal antiplatelet pharmacotherapy has a major impact on 
the post-procedural outcomes related to percutaneous coro-
nary intervention (PCI). Currently it involves a combination of 
aspirin and a P2Y12-inhibitor. Dual antiplatelet therapy should 
be continued for at least one month after bare metal stent 
implantation, and up to six months in cases of drug-eluting 
stents in interventions for stable angina [1, 2].
Although adding clopidogrel to aspirin monotherapy re-
duced the risk of ischaemic events in the elective PCI setting, 
response to clopidogrel is highly heterogeneous and depends 
on individual clinical characteristics and on the genetically de-
termined enzymatic activity of the cytochrome P450 enzyme 
system. Inadequate platelet inhibition and consequential high 
platelet reactivity (HPR) is associated with an increased risk 
of stent thrombosis and recurrent myocardial infarction (MI) 
in clopidogrel-treated patients after PCI. Similar to this, many 
reports have shown that patients with loss-of-function alleles 
are at higher risk for ischaemic events [3].
Administration of more potent antiplatelet agents, i.e. 
prasugrel or ticagrelor allows HPR to be overcome in most 
individuals who do not respond adequately to clopidogrel, 
identified either by genotyping or phenotyping [4–6]. However, 
clinical evidence from previously conducted trials on individu-
alised antiplatelet therapy in stable disease remains inconclusive 
and requires further exploration [7, 8]. Moreover, phenotyping 
and genotyping have never been compared in a head-to-head 
manner in trials of personalised antiplatelet therapy.
Our aim is to evaluate whether tailored P2Y12-inhibitor 
therapy by either bedside platelet or genetic testing may be 
superior to conventional approach in reducing the risk of 
periprocedural MI in stable angina patients undergoing PCI. 
This surrogate endpoint has been shown to correlate with 
survival and is relatively frequent among patients with stable 
coronary artery disease (CAD) [9]. Here we present the ra-
tionale and design of Optimal aNtiplatelet pharmacotherapy 
guided by bedSIDE genetic or functional TESTing in elective 
PCI patients (ONSIDE TEST) — a prospective, open-label, 
randomised parallel-group multicentre trial.
MeThODs
Rationale for platelet function testing
Clopidogrel is an oral thienopyridine that irreversibly inhibits 
the P2Y12 adenosine diphosphate receptor. One major limita-
tion of clopidogrel is the large inter-individual variability in the 
achieved level of platelet inhibition between patients, result-
ing in an unpredictable antiplatelet effect during fixed-dose 
treatment. As a consequence, approximately 20–30% of 
CAD patients of the Caucasian population demonstrate high 
on-treatment platelet reactivity, which is associated with 
higher risk for stent thrombosis, MI, and cardiovascular mor-
tality according to evidence from more than 25,000 patients 
[10, 11]. Most of the evidence is based on the results with 
the VerifyNow P2Y12 assay (Accumetrics, San Diego, CA), 
which measures platelet agglutination to fibrinogen-coated 
polystyrene droplets activated by adenosine diphosphate 
[12, 13] and provides results as platelet reactivity units (PRU). 
Several prior studies confirmed that patients with HPR, meas-
ured by the VerifyNow, have higher risk for periprocedural 
myonecrosis [14, 15].
Prasugrel is a potent, third-generation antiplatelet agent 
that shows faster onset of action and more potent inhibition 
of the P2Y12 receptor. The clinical result of the more rapid 
and more potent platelet inhibition by prasugrel has been 
demonstrated in the TRITON TIMI 38 trial, in which prasugrel 
reduced the risk of cardiovascular death, MI, or stroke by 19% 
compared to clopidogrel in acute coronary syndrome (ACS) 
patients undergoing PCI. However, this benefit was accompa-
nied by a higher risk for bleeding. Therefore, prasugrel may 
be a good candidate to overcome HPR in patients undergoing 
PCI and can be used in selected cases with stable CAD [16].
Rationale for genotyping  
of clopidogrel-treated patients
Clopidogrel activation by cytochrome P450 requires 
a two-step oxidation process, determined mostly by the 
activity of the CYP2C19 isoenzyme. Notably, a significant 
proportion of patients carry loss-of-function polymorphisms 
in CYP2C19, most commonly *2 (rs4244285) [17]. Individuals 
with loss-of-function alleles have lower levels of active me-
tabolite and have less potent platelet inhibition on-clopidogrel, 
resulting in higher prevalence of HPR [18, 19]. The clinical 
implication of such single nucleotide polymorphisms translates 
into a higher risk of mortality and stent thrombosis, with most 
of the data available for the *2 lost of function (LOF) allele 
[18–20]. A prior study has shown that overcoming HPR in 
*2 carriers by increasing the dose of clopidogrel is not effective 
[21, 22]. On the contrary, switching clopidogrel to prasugrel in 
heterozygous and homozygous loss-of-function carriers results 
in adequate platelet inhibition comparable to non-carriers [6].
Rationale for bedside testing
Even the most precise and advanced diagnostic methods 
are useless if they are not implemented in everyday clinical 
practice. Barriers comprise costs, poor logistics, high level of 
complexity for the operator, low accessibility, and little or no 
standardisation of the respective testing method. Traditional 
models of centralised hospital laboratories provide high-speed 
and high-throughput capabilities at reasonable pricing; how-
ever, they are associated with prolonged time from sample 
collection to final result. The bedside approach accelerates 
patient care decision-making, reduces errors, and promotes 
patient safety by eliminating process steps and handoffs. Most 
PCIs are performed in the acute coronary setting, which re-
quires rapid reaction and quick therapeutic decisions. Delays 
in reperfusion lead to increased risk of mortality, myocardial 
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injury, and heart failure. Stable CAD patients are usually 
admitted to the hospital for a short stay, even as a one-day 
admission, which drastically restricts the number of additional 
diagnostic tests performed before the PCI. Bedside testing 
is the most rational mode of assessment. The estimation of 
platelet function before PCI allows identification of individuals 
at risk and pursuing essential clinical action, i.e. optimisation 
of pharmacotherapy.
Rationale for a comparison of  
genotyping and phenotyping 
Prior studies confirmed that both genotyping for CYP2C19 *2 al-
leles and platelet function testing for HPR predicts a higher risk 
for ischaemic events in patients undergoing PCI. Both tests have 
possible advantages and disadvantages: for example, genotyp-
ing can be performed in clopidogrel-naïve patients, genotype 
is constant, but LOF alleles are only responsible for a minority 
in variability in clopidogrel effect, and platelet function testing 
is faster. Therefore, it would be important to compare these 
two approaches in the personalised antiplatelet approach. So 
far, platelet function testing has not been compared in a pro-
spective study in a head-to-head manner. 
Study objectives
The primary objective of the study is to test whether opti-
misation of P2Y12-inhibition based on either phenotyping 
or genotyping is able to reduce the risk of periprocedural 
MI compared to conventional care in patients undergoing 
elective PCI. 
Study population and eligibility criteria
The ONSIDE TEST is an investigator-initiated, phase IV, 
multicentre, prospective, open-label, randomised controlled 
clinical trial involving investigational centres in Poland and 
Hungary. This study is registered with ClinicalTrials.gov, num-
ber NCT01930773. The investigators obtained independent 
research grants from non-commercial sources.
The study includes stable CAD patients between 18 and 
75 years of age scheduled for an elective PCI with stent im-
plantation, based on coronary angiography. The exclusion 
criteria are ACS, any elevation of myocardial necrosis enzymes 
at screening, planned administration of glycoprotein IIb/IIIa 
inhibitors for PCI, PCI for chronic total occlusions, lesions 
with extensive calcifications requiring rotational atherec-
tomy, low platelet count (< 70 000/µL), high bleeding risk, 
coronary artery bypass surgery in the previous three months, 
severe chronic renal failure (estimated glomerular filtration 
rate < 30 mL/min), requirement for oral anticoagulation (war-
farin, dabigatran, apixaban, rivaroxaban, etc.), history of stroke 
or transient ischaemic attacks, weight < 60 kg, known bleeding 
diathesis, haematocrit of < 30% or > 52%, and pregnancy. 
Randomisation, patient flow, and study intervention
Patients who fulfil all inclusion criteria and none of the 
exclusion criteria, and who sign informed consent will be 
randomised with an electronic randomisation tool for iPhone 
[Randomizer for Clinical Trial, MEDSHARING, Fontenay Sous 
Bois, France] into three arms: 1) phenotyping arm, 2) genotyp-
ing arm, and 3) control arm [23].
Phenotyping arm
In the phenotyping arm, treatment decisions are based on 
the test results of the VerifyNow P2Y12 assay. Patients who 
are not on long-term pretreatment with clopidogrel before 
PCI (at least five days on 75 mg clopidogrel) will receive 
a loading dose of 600 mg of clopidogrel after angiography 
just after randomisation. Platelet function testing will be 
performed at least 6 h after 600 mg loading dose, or after 
coronary angiography in patients adequately pretreated 
with clopidogrel. The cutoff point of 208 PRU will be used 
to identify patients with HPR. Those with values above this 
threshold will receive a loading dose of 60 mg of prasugrel. 
The PCI will be performed 1–2 h after prasugrel loading to 
allow the drug to reveal its full potency [24]. Directly before 
the procedure, platelet function testing will be repeated to 
evaluate the current on-prasugrel platelet reactivity. After 
PCI, patients will be treated for seven days with 10 mg of 
prasugrel daily. Consecutive choice of P2Y12 inhibitor will 
be at the discretion of a primary care physician or cardi-
ologist based on individual patient characteristics, clinical 
scenario, drug availability, and economic capabilities. At 
this time point a switch to clopidogrel is allowed. Patients 
without HPR will go to the PCI procedure on standard 75 mg 
clopidogrel therapy.  
Genotyping arm
The genotyping arm will be tested using a bedside cheek swab 
Spartan RX CYP2C19 System (Ottawa, Ontario, Canada). Ho-
mozygous and heterozygous carriers of loss-of-function poly-
morphism *2 (poor metabolisers), in whom the metabolism of 
prodrug to active clopidogrel is impaired, will receive a loading 
dose of 60 mg of prasugrel 1–2 h before PCI. Directly before 
the procedure, platelet function testing will be performed to 
evaluate the current on-prasugrel platelet reactivity. After PCI, 
patients with *2 LOF alleles will be treated for seven days with 
a daily dose of 10 mg prasugrel. Subjects with wild-type alleles 
will be loaded with clopidogrel, if naïve, or will continue the 
clopidogrel therapy according to pretreatment. Although the 
loss-of-function *3–*8 alleles’ polymorphisms are also as-
sociated with poor clopidogrel metabolism, they will not be 
assessed in this study as their frequency is < 1% in the general 
population and such additional analysis would significantly 
increase the overall cost [25].
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Control arm
Patients randomised to the control arm will follow the conven-
tional pathway receiving standard doses of clopidogrel (75 mg 
daily) and proceed without any additional testing as indicated 
by the current European Society of Cardiology guidelines on 
the management of stable CAD [16]. A flow chart of the study 
is provided in Figure 1. 
Monitoring of myocardial injury
The trials in stable CAD conducted so far, such as TRIG-
GER-PCI, assessed hard clinical endpoints. The incidence 
of major adverse cardiac event in this particular population 
and especially in the in the era of modern drug eluting stents 
is low and requires very large cohort of patients to evaluate. 
Therefore, a more appealing approach is to assess a surrogate 
endpoint that clearly correlates with long-term clinical out-
comes, such as periprocedural myonecrosis biomarkers. We 
will measure troponin I and creatine kinase muscle brain 
(CK-MB) before PCI to exclude patients with baseline myo-
cardial injury or infarction. Blood samples will be drawn at 
prespecified intervals: 2 h, 8 h, and 24 h after PCI, to detect 
the rise in cardiac enzymes. Periprocedural myocardial injury 
is defined as elevation of troponin I > 1× 99th percentile 
upper limit of norm (ULN), but < 5× 99th percentile ULN 
or elevation of troponin I > 5× ULN in the absence of an-
giographic or imaging findings of ischaemia. Periprocedural 
MI will be recognised in patients with troponin elevation 
5× > 99th percentile ULN and one of the following: 1) chest 
pain for longer than 20 min, 2) ischaemic ST changes or new 
pathological Q waves, 3) angiographic evidence of a flow 
limiting complication, or 4) imaging evidence of myocardial 
ischaemia [26].
Moreover, MI associated with stent thrombosis will be 
diagnosed after its detection by coronary angiography or 
autopsy in the setting of myocardial ischaemia together with 
a rise of troponin levels with at least one value > 99th per-
centile ULN [26].
Periprocedural myocardial biomarker leak is defined as 
a troponin or CK-MB elevation greater than 1× of the ULN 
within 24 h of elective PCI.
Study outcomes
Primary outcomes. The primary outcome measure is the 
prevalence of periprocedural myocardial injury within 24 h 
Figure 1. Optimal aNtiplatelet pharmacotherapy guided by bedSIDE genetic or functional TESTing in elective PCI patients  
(ONSIDE TEST) — study design diagram; CK-MB — creatine kinase muscle brain; LD — loading dose; PCI — percutaneous  
coronary intervention; PRU — platelet reactivity unit; R — randomisation 
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after PCI in the genotyping and the phenotyping groups as 
compared to the controls.
Secondary outcomes. The secondary endpoints include: 
 — maximum level of CK-MB elevation within 24 h after PCI;
 — maximum troponin elevation within 24 h after PCI;
 — mean PRU during PCI;
 — prevalence of inadequate platelet inhibition during PCI 
(PRU > 208);
 — prevalence of periprocedural MI;
 — prevalence of periprocedural myocardial biomarker leak;
 — cardiac death, MI, definite or probable stent thrombosis, 
or urgent repeat revascularisation occurring within 30 days. 
The secondary end-points will be assessed as a com-
parison between all three groups as well as between the 
controls and the bedside tested cohort (genotyping plus the 
phenotyping groups).
Safety outcomes
Among safety outcomes bleeding will be assessed according to 
the Bleeding Academic Research Consortium (BARC) defini-
tion [27]. Any clinical, laboratory, and/or imaging evidence of 
bleeding that triggers healthcare provider response (type 3) 
as well as any fatal bleeding (type 5) will be reported within 
seven days and 30 days after index procedure. All primary 
and secondary outcome measures are presented in Table 1.
Clinical follow-up
All patients will be followed-up until 30 days and six months 
after PCI either by phone or during clinical visits. 
Statistical considerations
The sample size analysis was performed based on the pub-
lished data on the prevalence of periprocedural MI in the 
stable CAD population undergoing elective stent implantation 
[11, 28]. The potential degree of reduction of this end-point 
using a more potent antiplatelet agent was based on the data 
from a randomised trial in which the impact of prasugrel in 
periprocedural MI in stable CAD was assessed [29]. Using 
the Fleiss method with continuity correction we estimated 
the sample size at 362 patients assuming the prevalence of 
periprocedural MI in the control group at 33% with 80% 
power to detect a clinically meaningful reduction to 25% of 
the event rates in the study group with a type I error of 5% 
(two-sided). 
Statistical analysis
All analyses will be performed on end points verified by the 
independent cardiology clinical events committee. Efficacy 
analyses will be based on an intention-to-treat population, 
which will include all eligible patients enrolled in the study, 
and safety analyses will be done using the treated data set. 
Categorical variables expressed as counts and percentages will 
be compared using c2 or Fisher exact test, whereas continuous 
variables expressed as mean ± standard deviation (SD) will be 
compared using the Wilcoxon rank-sum test. Data collected 
during follow-up will be analysed using appropriate univariate 
and multivariate techniques. Patients lost to follow-up will be 
censored on the date of last follow-up. Freedom from any 
major adverse cardiac event and overall survival will be as-
sessed according to Kaplan-Meier, providing medians with 
95% confidence intervals. The respective outcome measure 
comparisons between the aggregometry, genotyping, and 
control arms and between on-prasugrel and on-clopidogrel 
groups will be performed using the log-rank test. The potential 
influence of baseline risk factors on observed results will be as-
sessed with the use of the Cox proportional hazards regression 
model. When hypotheses regarding risks cannot be suitably 
analysed with the Cox model, alternative statistical models 
will be used. In addition, multivariate models will be carried 
out for key bleeding variables (BARC defined type 3 and 
type 5 bleedings). All hypothesis tests will be two-sided, and 
a p value of < 0.05 will be considered statistically significant. 
The three arms will be compared between each other, and 
additionally the combined genotyping and phenotyping group 
will be compared with the control arm. Statistical analyses will 
be performed with SAS (version 9.2 or newer, SAS Institute 
Inc., Cary, North Carolina).
Table 1. Outcome measures
Primary outcome measures
• The maximum level of CK-MB elevation within 24 h of elective PCI
Secondary outcome measures
• Periprocedural myocardial injury is defined as a troponin eleva-
tion greater than 5× of the ULN within 24 h of elective PCI
Other outcome measures
• The level of peak troponin-I elevation during 24 h of elective PCI
• The rate of periprocedural MI defined as a peak troponin-I value 
greater than 5× the ULN and one of the following: 1) chest 
pain above 20 min, 2) ischaemic ST changes or new patho-
logical Q waves, 3) angiographic evidence of a flow limiting 
complication, or 4) imaging evidence of myocardial ischaemia 
within 24 h
• Periprocedural myocardial biomarker leak is defined as a tro-
ponin or CK-MB elevation greater than 1× of the ULN within 
24 h of elective PCI
• BARC-defined type 3 (clinical, laboratory, and/or imaging evi-
dence of bleeding, with healthcare provider responses) and  
type 5 (fatal) bleeds happening within seven days of PCI
• The rate of cardiac death, MI, definite or probable stent  
thrombosis or urgent repeat revascularisation within  
30 days of elective PCI
CK-MB — creatine kinase muscle brain; PCI — percutaneous coronary 
intervention; ULN — upper limit of norm; MI — myocardial infarction; 
BARC — bleeding definition by the Bleeding Academic Research Con-
sortium [27]
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DIsCUssION
Many previous studies failed to identify the proper strategy 
to optimise antiplatelet therapy in patients undergoing PCI. 
Close scrutiny of methodologies revealed important aspects 
that influenced their results. Firstly, increased dosages of clopi-
dogrel are not sufficient to decrease platelet reactivity in HPR 
patients. This was shown in the ARCTIC trial (Assessment by 
a Double Randomisation of a Conventional Antiplatelet Strat-
egy vs. a Monitoring-guided Strategy for Drug-Eluting Stent 
Implantation and of Treatment Interruption vs. Continuation 
One Year after Stenting). The study assessed if the adjustment 
of antiplatelet therapy in the study group based on platelet 
monitoring (monitoring arm) was superior to standard dose of 
clopidogrel. Although among the HPR patients the protocol 
allowed the increase of clopidogrel to 150 mg or switch to 
10 mg of prasugrel, the later approach was very low (3.3%). 
The study showed no benefit of increased dose of clopidogrel 
in HPR in relation to the primary endpoint of death, MI, stent 
thrombosis, stroke, or urgent revascularisation after one year 
(HR 1.13, 95% CI 0.98–1.29) [30]. Similarly, a high dose 
of clopidogrel was also tested in the GRAVITAS trial, which 
showed no advantage in primary end point (cardiovascular 
death, non-fatal MI, or stent thrombosis) [12]. Secondly, 
the incidence of hard endpoints (cardiovascular death, MI) 
is very low among stable patients treated with current PCI 
techniques, making it very difficult to design and conduct an 
adequately powered trial. This was well exemplified by the 
TRIGGER-PCI study, which aimed to assess whether the risk 
of cardiovascular mortality or MI in low-risk CAD patients 
with high on-clopidogrel platelet reactivity after elective PCI 
with drug-eluting stents can be reduced by switching from 
clopidogrel to prasugrel [8]. The interim analysis revealed 
very low numbers of events in both arms (0% in prasugrel 
arm vs. 0.5% in clopidogrel arm, p = NS) and led to early 
termination due to futility. 
A higher number of endpoints was observed in the 3T/2R 
trial, in which periprocedural MI was chosen as the primary 
endpoint. This was a prospective, randomised, open-label, 
controlled trial that assessed the tailored treatment with an 
IIb/IIIa inhibitor, tirofiban, in patients with poor response to as-
pirin and/or clopidogrel, and elevation of troponin 3× > 99th 
percentile ULN within 48 h after completion of the PCI was 
chosen as the primary end-point [7]. In this trial administration 
of IIb/IIIa significantly reduced the incidence of periprocedural 
MI in the study group; however, this was achieved at the cost 
of a higher rate of bleedings. A poor response to standard 
doses of clopidogrel is genetically conditioned as was shown 
by the RAPID GENE study. This proof-of-concept, prospec-
tive, randomised trial tested the genotype-based strategy to 
reduce the incidence of on-treatment HPR. So far there are 
no randomised trials designed to demonstrate superiority of 
the strategy of administration of a more potent P2Y12 inhibi-
tor, i.e. prasugrel, in suboptimal responders to clopidogrel, 
as compared with conventional strategy with standard dose 
of oral antiplatelet medications. 
sUMMARY
The ONSIDE TEST trial is an open-label, randomised, 
parallel-group, multicentre, international trial comparing 
bedside genetic and pharmacodynamic testing of resistance 
to clopidogrel in patients undergoing elective PCI. 
This is the first study with a head-to-head comparison of 
the above bedside testing modalities in patients with stable 
CAD qualified for percutaneous revascularisation. The trial 
is expected to verify the impact of the tailored anti-platelet 
therapy, based on the point-of-care genetic or platelet function 
testing, on the periprocedural myocardial injury. Furthermore, 
the ONSIDE TEST trial will provide important information 
regarding the safety and efficacy of prasugrel and will show 
whether more potent P2Y12 inhibition is superior to the current 
standard of care in patients with HPR, who are likely not to 
benefit fully from clopidogrel. 
Trial status
The trial is currently undergoing with 50 patients being suc-
cessfully randomised. The estimated final data collection 
date is March 2019 (for primary outcome measure), and the 
expected study completion date is May 2019.
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S t r e s z c z e n i e
Wstęp i cel: Wysoka reaktywność płytek i nosicielstwo mutacji genu CYP2C19 wiążą się z podwyższonym ryzykiem około-
zabiegowego zawału serca u pacjentów poddawanych planowej angioplastyce wieńcowej. Mimo przesłanek teoretycznych 
brakuje dedykowanych badań klinicznych oceniających, czy zastosowanie spersonalizowanej farmakoterapii uwzględniającej 
wyniki przyłóżkowych testów funkcji płytek i genotypowania pozwoliłoby ograniczyć liczbę tych powikłań.
Metody: ONSIDE-TEST to wieloośrodkowe, prospektywne, otwarte, kontrolowane badanie kliniczne z randomizacją, które-
go celem jest ocena, czy optymalizacja terapii przeciwpłytkowej z uwzględnieniem wyników agregometrii i genotypowania 
przynosi dodatkowe korzyści kliniczne względem standardowego postępowania. Pacjenci będą randomizowani do trzech 
ramion badania: 1) agregometria, 2) genotypowanie, 3) grupa kontrolna. W grupie 1 agregometria będzie przeprowadzana za 
pomocą urządzenia VerifyNow P2Y12 przed wykonaniem angioplastyki, chorzy z wynikiem reaktywności płytek > 208 otrzy-
mają prasugrel. W grupie genotypowania nosiciele mutacji *2 zostaną poddani terapii prasugrelem. Pozostali chorzy, w tym 
osoby w grupie kontrolnej, będą stosować klopidogrel. Pierwszorzędowym punktem końcowym badania jest częstość około-
zabiegowego zawału serca stwierdzanego w ciągu 24 h od angioplastyki. Do drugorzędowych punktów końcowych należą: 
wystąpienie zgonu sercowo-naczyniowego, zawału serca, pewnej lub prawdopodobnej zakrzepicy w stencie oraz ponowna 
rewaskularyzacja w ciągu 30 dni od implantacji stentu. W zakresie oceny bezpieczeństwa będzie oceniane ryzyko krwawień 
typu 3 i 5 wg skali Bleeding­Academic­Research­Consortium (BARC) w ciągu 30 dni od zabiegu angioplastyki.
Podsumowanie: Badanie ONSIDE-TEST służy sprawdzeniu, czy strategia personalizacji farmakoterapii przeciwpłytkowej 
przy zastosowaniu przyłóżkowych testów agregometrycznych i genotypowania pozwoli na redukcję liczby okołozabiegowych 
zawałów serca.
Rejestracja badania: ClinicalTrials.gov: NCT01930773.
Słowa kluczowe: personalizacja farmakoterapii, leczenie przeciwpłytkowe, wysoka reaktywność płytek CYP2C19*2,  
klopidogrel, prasugrel, stabilna choroba wieńcowa, angioplastyka
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